fda warning letters compounded semaglutide october 2025 compounding Week Ending October 31, 2025: Featuring a Panel of FDA Compliance Leaders Discussing Key Current Concerns Hims & Hers' Woes Compound

5 Dietary carrageenans and intestinal microflora

The metabolic syndrome: similar deleterious impact on all-cause mortality in hypertensive and normotensive subjects

You can work with your provider to optimize your medication protocol, your peptide strategy, and your metabolic health

Its a temporary CMS demonstration that lets eligible Medicare Part D beneficiaries access GLP-1 medications prescribed solely for weight loss at a $50 monthly copay

Lack of Safety Seals or Tamper-Proof Packaging Many brands now use security features to protect their products: Holographic stickers Shrink bands Safety seals or tabs If these are missing or damaged, the product may not be safe